Yousif Capital Management LLC Invests $275,000 in Royalty Pharma PLC (NASDAQ:RPRX)

Yousif Capital Management LLC purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 8,824 shares of the biopharmaceutical company's stock, valued at approximately $275,000.

Several other large investors have also recently modified their holdings of RPRX. Vontobel Holding Ltd. bought a new stake in Royalty Pharma in the fourth quarter valued at approximately $230,000. Allworth Financial LP increased its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after purchasing an additional 388 shares during the period. CIBC Asset Management Inc boosted its holdings in Royalty Pharma by 4.1% in the fourth quarter. CIBC Asset Management Inc now owns 26,119 shares of the biopharmaceutical company's stock worth $666,000 after acquiring an additional 1,028 shares in the last quarter. Finally, Truist Financial Corp bought a new position in shares of Royalty Pharma in the 4th quarter worth $371,000. Institutional investors own 54.35% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on RPRX. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Wall Street Zen raised Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Morgan Stanley assumed coverage on Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and an average price target of $47.33.

Royalty Pharma Price Performance

Shares of RPRX traded down $0.05 during mid-day trading on Friday, reaching $34.86. 5,346,891 shares of the stock traded hands, compared to its average volume of 3,648,461. The company has a market cap of $19.60 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 1.79 and a beta of 0.48. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $35.38. The firm has a fifty day moving average price of $33.14 and a 200 day moving average price of $31.25. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.68.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a return on equity of 24.71% and a net margin of 48.23%. As a group, equities research analysts predict that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.52%. Royalty Pharma's dividend payout ratio is currently 47.57%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.